Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
VANCOUVER, British Columbia and BOSTON, Aug. 01, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused…
1,046€
-1,88%
Echtzeit-Aktienkurs Algernon Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Algernon Pharmaceuticals Inc. Aktie
Algernon Closes NoBrainer Imaging Centers, Inc. Acquisition
VANCOUVER, British Columbia, May 22, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…
Xenon Pharmaceuticals Inc. (XENE) Q1 2025 Earnings Call Transcript
…
Xenon Pharmaceuticals Inc. (XENE) Q4 2024 Earnings Call Transcript
…
Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference
VANCOUVER, British Columbia and BOSTON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused…
Xenon Pharmaceuticals Inc. (XENE) Q3 2024 Earnings Call Transcript
…
Algernon Pharmaceuticals Announces Closing of Private Placement
VANCOUVER, British Columbia, Aug. 02, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the…
Xenon Pharmaceuticals Inc. (XENE) Q1 2024 Earnings Call Transcript
…
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
VANCOUVER, British Columbia, April 24, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “AGN Pharma”) (CSE: AGN)…
Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting
VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neuroscience-focused biopharmaceutical company, announced…
Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Researchs Pitch, Deep Dive and Q&A Webinar on April 16th, 2024
VANCOUVER, British Columbia, April 11, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…
Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset
VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT:…
Algernon Pharmaceuticals Strikes Deal to Advance Ifenprodil in Chronic Cough Treatment
…
Algernon Pharmaceuticals closes $2M acquisition of its chronic cough research program by Seyltx
Algernon Pharmaceuticals Inc. (CSE:AGN, OTCQB:AGNPF) has finalized the acquisition of its NP-120 (Ifenprodil) research program by US-based Seyltx Inc in…
Xenon Pharmaceuticals Inc. (XENE) Q4 2023 Earnings Call Transcript
…